Light and Shadow of Na-Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Points for Improvement Based on Our Clinical Experience
Table 1
Background of target patients at starting treatment.
Patients (n = 236)※
※ Patients have been taking SGLT2 inhibitors alone or with the other antidiabetic drugs for at least two years
HbA1c (glico hemoglobin A1c)
9.1 ± 1.7
%
Sex (M/F)
152/84
Age
61.4 ± 12.4
years
Male
61.6 ± 12.9
years
Female
61.0 ± 11.4
years
BMI (body mass index)
27.1 ± 5.2
kg/m2
Male
26.6 ± 5.1
kg/m2
Female
28.0 ± 5.2
kg/m2
Hct (hematocrit)
43.0 ± 4.2
%
TP (total protein)
7.50 ± 0.48
g/dL
ALB (albumin)
4.19 ± 0.40
g/dL
AST (aspartate aminotransferase)
27.4 ± 17.2
U/L
ALT (alanine aminotransferase)
33.1 ± 23.8
U/L
γ-GTP (γ-glutamyl transpeptidase)
49.7 ± 51.4
U/L
TG (triglyceride)
186.8 ± 119.0
mg/dL
HDL-C (HDL-cholesterol)
51.6 ± 16.3
mg/dL
LDL-C (LDL-cholesterol)
118.1 ± 35.3
mg/dL
BUN (urea nitrogen)
16.62 ± 5.48
mg/dL
Cre (creatinine)
0.766 ± 0.255
mg/dL
BUN/Cre (BUN Cre ratio)
23.0 ± 7.0
eGFR (estimated glomerular filtration rate)
81.0 ± 27.8
mL/min/1.73 m2
UA (uric acid)
5.63 ± 1.47
mg/dL
Na (sodium)
139.5 ± 2.6
mmol/L
K (potassium)
4.30 ± 0.41
mmol/L
Mean ± SD
Marks are items used as explanatory variables in logistic regression analysis.